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Inhibition of IL-1R1/MyD88 signalling promotes
mesenchymal stem cell-driven tissue regeneration
Mikae¨l M. Martino1, Kenta Maruyama1, Gisela A. Kuhn2, Takashi Satoh1, Osamu Takeuchi1,3, Ralph Mu¨ller2 &
Shizuo Akira1
Tissue injury and the healing response lead to the release of endogenous danger signals
including Toll-like receptor (TLR) and interleukin-1 receptor, type 1 (IL-1R1) ligands,
which modulate the immune microenvironment. Because TLRs and IL-1R1 have been shown
to inﬂuence the repair process of various tissues, we explored their role during bone
regeneration, seeking to design regenerative strategies integrating a control of their signalling.
Here we show that IL-1R1/MyD88 signalling negatively regulates bone regeneration,
in the mouse. Furthermore, IL-1b which is released at the bone injury site, inhibits the
regenerative capacities of mesenchymal stem cells (MSCs). Mechanistically, IL-1R1/MyD88
signalling impairs MSC proliferation, migration and differentiation by inhibiting the
Akt/GSK-3b/b-catenin pathway. Lastly, as a proof of concept, we engineer a MSC delivery
system integrating inhibitors of IL-1R1/MyD88 signalling. Using this strategy, we considerably
improve MSC-based bone regeneration in the mouse, demonstrating that this approach may
be useful in regenerative medicine applications.
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A
lthough, the advancement of regenerative medicine will
play a vital role in meeting the future healthcare
challenges, the promises of regenerative therapies remain
largely unrealized. For designing effective regenerative medicine
strategies, we should better understand the interactions between
the multiple actors that shape a regenerative environment. In
particular, tissue injury is generally associated with an immune
response, which is most likely a key regulator of the healing
process1,2. Hence, in-depth understanding of the role of the
immune system during tissue repair and regeneration could
provide clues to therapeutic avenues for restoring damaged
tissues, and controlling the immune regulations of tissue healing
may become an attractive option in regenerative medicine1,2.
Unlike most tissues, bone possesses an innate capacity to
regenerate following injury. The majority of bony injuries, when
properly treated by re-apposition, heal without a permanent
lesion. However, many clinical indications remain that require
therapeutic intervention to augment bone regeneration such as
large craniomaxillofacial defects, bone degeneration in patients
with osteonecrosis, distal tibial fractures and periodontal
disease3,4. Autologous bone grafting is currently the gold
standard, but this approach is associated with numerous
drawbacks, including donor-site morbidity, the availability of
limited grafting material and compromised bone quality in
patients with osteoporosis5. Therefore, extensive efforts have been
made to develop bone regenerative strategies using various
combinations of cells4, growth factors6 and biomaterials7.
However, only few of these strategies have translated into
clinical practice and none of them have become a standard
in regenerative medicine. Efﬁcacy, safety, practical, cost-
effectiveness and regulatory issues often prevent the widespread
therapeutic use of bone regenerative therapies4,8. In addition, one
of the major challenges lies in the limited understanding of the
cellular and molecular mechanisms that should be targeted to
promote bone regeneration. Especially, understanding and
subsequently controlling the immune regulations of bone
regeneration could be crucial to improve the effectiveness of
bone regenerative therapies1,2,9.
Commonly, tissue injury and the healing response lead to the
release of various endogenous danger signals including Toll-like
receptor (TLR) and interleukin-1 receptor, type 1 (IL-1R1)
ligands10,11, which modulate the immune microenvironment.
These danger signals are involved in the recruitment and the
activation of immune cells engaged in host defence11,12. In
addition, TLRs and IL-1R1 have been shown to inﬂuence the
repair process of several tissues13–23. For example, the injury
promoting effects of TLR4 is apparent in many organs, as seen by
the protection of TLR4-mutant or -deﬁcient mice after hepatic,
renal, cardiac and cerebral ischemia reperfusion13–16,19. Similarly,
IL-1R1 signalling critically regulates infarct healing17 and
disruption of IL-1 signalling can improve the quality of wound
healing18,21.
In this study, we explore the role of TLRs and IL-1R1 during
bone regeneration, seeking to design regenerative strategies
integrating a control of their signalling. We show that IL-1R1
signalling via the adaptor protein MyD88 negatively regulates
bone regeneration, in the mouse. IL-1b is released at the bone
injury site and inhibits the regenerative capacities of mesench-
ymal stem cells (MSCs). Mechanistically, IL-1R1/MyD88 signal-
ling impairs MSC migration, proliferation and differentiation into
osteoblasts, by inhibiting the Akt/GSK-3b/b-catenin pathway.
Furthermore, we propose a MSC delivery system integrating
inhibitors of IL-1R1/MyD88 signalling. Using this approach, we
signiﬁcantly improve MSC-based bone regeneration in a mouse
critical size calvarial defect model, demonstrating that this
approach may be useful in regenerative medicine applications.
Results
IL-1R1/MyD88 signalling negatively regulates bone regeneration.
To evaluate the role of TLRs and IL-1R1 during bone regenera-
tion, we ﬁrst analysed regeneration in mice deﬁcient for MyD88
and TRIF, which are key adaptor proteins involved in TLR and
IL-1R1 signalling transduction12. Among the available orthotopic
models used for evaluating bone regeneration, we chose the
critical size calvarial defect, because this model have gained a
widespread reputation and use in the published literature,
reporting valuable data from basic and applied research24.
Moreover, the critical size calvarial defect model is very reliable
and displays low variability25, making it ideal to compare bone
regeneration in multiple knockout mice. Critical size calvarial
bone defects (5mm diameter) were created and ﬁlled with a
standard ﬁbrin matrix. The ﬁbrin matrix was used to ensure clot
formation in the defect and to standardize the model8, while the
procedure did not signiﬁcantly inﬂuence bone regeneration
(Supplementary Fig. 1). Remarkably, 4 weeks post surgery,
Myd88 / mice displayed a faster regeneration characterized by
a better coverage of the defect with mineralized bone (Fig. 1a,b),
suggesting that TLR1, TLR2, TLR4–9, and/or IL-1R1 inﬂuence
bone regeneration, since their signalling depends on MyD88 (ref.
12). When bone regeneration was analysed in Tlr1 / , Tlr2/4/
9 / (triple knockout), Tlr5 / , Tlr7 / and Il1r1 / mice,
only Il1r1 / mice displayed better healing (Fig. 1c,d), indicating
that IL-1R1/MyD88 signalling negatively regulates bone
regeneration.
IL-1R1/MyD88 signalling inhibits MSC-driven bone regeneration.
Since IL-1R1/MyD88 signalling is well known for inducing
mobilization and activation of immune cells26, we determined
whether this signalling inhibits bone regeneration by acting on
the immune cells recruited after injury and throughout the
regeneration process. As a model, we reconstituted lethally
irradiated wild-type (wt) mice by intravenously injecting bone
marrow cells from Myd88 / mice, to have chimeric mice
with bone marrow-derived immune cells unable to transduce
IL-1R1/MyD88 signalling (Supplementary Fig. 2). While very few
Myd88 / bone marrow MSCs could have been transferred in
wt mice (0.001–0.01% of injected cells), Myd88 / MSCs most
likely did not populate the bone marrow of irradiated wt mice,
since the vast majority of MSCs does not go beyond lung and
liver following intravenous injection27,28. Interestingly, Myd88 /
 chimeric mice did not display better healing (Fig. 1e,f),
suggesting that IL-1R1/MyD88 signalling negatively regulates
bone regeneration by acting on tissue-resident cells. Since
osteoclasts derive from bone marrow monocytes, they were
lacking MyD88 in Myd88 / chimeric mice. Therefore, we
hypothesized that IL-1R1/MyD88 signalling negatively regulates
bone regeneration by acting on osteoblasts and/or skeletal
stem/progenitor cells including MSCs29–33.
To test whether IL-1R1/MyD88 signalling inﬂuences MSC-
driven bone regeneration, we delivered syngeneic MSCs derived
from bone of wt, Myd88 / or Il1r1 / mice into calvarial
defects of wt mice, and we analysed regeneration after 4 weeks.
MSCs from ﬁve isolates were pulled together and expended for
three passages (Supplementary Fig. 3), before being delivered in
bone defects through a ﬁbrin matrix. Delivering wt MSCs resulted
into a very slight improvement of regeneration compared with
treatment without cells. In contrast, delivering Myd88 / or
Il1r1 / MSCs induced signiﬁcantly better regeneration
(Fig. 1g,h). To check if the regeneration stimulated by Myd88 /
and Il1r1 / MSCs relied on a better intrinsic capacity of these
cells to differentiate towards osteoblasts or to proliferate, we
compared them with wt MSCs in vitro. Without IL-1R1 ligands
added to the cell culture medium, Myd88 / , Il1r1 / and wt
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MSCs showed equal ability to differentiate and to proliferate
(Supplementary Fig. 4). Therefore, we hypothesized that the
better regeneration induced by Myd88 / and Il1r1 / MSCs
was due to their inability to sense IL-1R1 ligands present at the
injury site.
IL-1b signalling via IL-1R1/MyD88 inhibits MSC functions.
Using a cytokine array, we proﬁled the cytokines present in the
bone defect microenvironment during the ﬁrst 2 weeks following
injury (Supplementary Fig. 5). Importantly, among IL-1R1
ligands26, IL-1b as well as IL-1 receptor antagonist (IL-1Ra) were
present at relatively high concentration within the ﬁrst 10 days
(Fig. 2a,b). After 10 days, IL-1b concentration starts to decline,
while IL-1Ra concentration drastically increases afterwards,
suggesting that the IL-1R1/MyD88 signalling occurs for at least
1 week post injury. Moreover, to gain insights about the cell types



































































Figure 2 | IL-1b is present at a signiﬁcant concentration in bone defects within the ﬁrst 10 days following injury. (a–c) Calvarial defects (4mm
diameter) were treated with ﬁbrin matrices. Fibrin matrices and bone tissue surrounding the defects (1mm farther) were collected at different time points.
Interleukins present in the harvested tissues and in ﬁbrin matrices were detected using an antibody array (a) and by enzyme-linked immunosorbent assay
(b,c). (c) IL-1b concentrations found in mice that have been treated with control or clodronate liposomes (lip.). For panels a–c, data are means±s.e.m.
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Figure 1 | IL-1R1/MyD88 signalling negatively regulates MSC-driven bone regeneration. Critical size calvarial defects (5mm diameter) in mice were
treated with a ﬁbrin matrix. Four weeks after treatment, bone regeneration was measured by microCTas coverage of the defect. (a,b) Regeneration in wt,
Myd88 / and Trif/ mice. (c,d) Regeneration in wt, Tlr1 / , Tlr5 / , Tlr7 / , Tlr2/4/9 / (triple knockout), Il1r1 / and in wt mice where
10 ng of IL-1b was co-delivered. (e,f) Regeneration in irradiated wt mice having received a bone marrow transplant from wt or Myd88 / mice.
(g,h) Regeneration in wt mice induced by syngeneic wt, Myd88 / or Il1r1 / MSCs delivered in ﬁbrin matrix. For a,c,e and g, data are means±s.e.m.
(nZ6 per condition). ANOVAwith Bonferroni post hoc test for pair-wise comparisons; ***Po0.001. Representative calvarial reconstructions are shown in b,
d,f and h. Original defect area is shaded with a red dotted outline. ANOVA, analysis of variance.
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releasing IL-1b, we quantiﬁed the concentration of the cytokine
in calvarial defects of mice where monocytes/macrophages
were depleted by clodronate liposomes34, since these cells are
known to release a large amount of IL-1b (ref. 26). In mice
depleted of monocytes/macrophages (Supplementary Fig. 6), the
concentration of IL-1b was about twice lower during the ﬁrst 6
days following injury (Fig. 2c), demonstrating that monocytes/
macrophages signiﬁcantly contribute to the presence of IL-1b.
Next, we explored the impact of IL-1R1/MyD88 signalling on
the regenerative capacities of MSCs. We focused on colony
formation, proliferation, migration, differentiation and trophic
function (for example, secretion of growth factors), considering
that these functions are critical for the regenerative potential of
MSCs. When primary (uncultured) bone-derived MSCs were
seeded in the presence of IL-1b (1 ngml 1), ﬁbroblast colony-
forming units (c.f.u.-F) and the average size of colonies were
signiﬁcantly lower (Fig. 3a,b; Supplementary Fig. 7a–c). In
addition, IL-1b (1 ngml 1) drastically inhibited the differentia-
tion of the colonies towards osteoblasts (Fig. 3c; Supplementary
Fig. 7d). Then, we analysed the effect of IL-1b on proliferation,
migration, differentiation and trophic function, of bone-derived
MSCs that have been expanded for three passages. Secretion of
trophic factors from MSCs was not affected by IL-1b
(Supplementary Fig. 8). Yet, IL-1b considerably inhibited MSC
proliferation, when cells were co-stimulated with serum or with
platelet-derived growth factor-BB (PDGF-BB), which is potent
proliferation and migration factor for MSCs35 (Fig. 3d;
Supplementary Fig. 9a). Similarly, transwell migration of MSCs
towards serum or PDGF-BB was inhibited by IL-1b (Fig. 3e;
Supplementary Fig. 9b). Regarding MSC differentiation, a single
stimulation with a low concentration of IL-1b (1 ngml 1)
severely inhibited their differentiation into osteoblasts (Fig. 3f,g;
Supplementary Fig. 9c) and into chondrocytes (Supplementary
Fig. 10). In addition, proliferation, migration and osteoblastic
differentiation of MSCs lacking IL-1R1 and/or MyD88 were not
affected by IL-1b (Supplementary Fig. 11), conﬁrming that the
IL-1R1/MyD88 signalling pathway is responsible for the
inhibitory effects of the cytokine. Notably, IL-1b inhibited
colony formation, proliferation, migration and osteoblastic
differentiation of bone marrow-derived MSCs (Supplementary
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Figure 3 | IL-1b inhibits c.f.u.-F proliferation migration and osteoblastic differentiation of MSCs. (a,b) Primary MSCs were seeded with or without IL-1b
(1 ngml 1 during 6 days). Graphs show c.f.u.-F and average size of colonies. Data are means±s.e.m. (n¼6 independent isolates). Representative wells
(9 cm2) are shown in b. (c) Primary MSCs were seeded in osteogenesis induction medium (OIM) for 28 days with or without IL-1b (1 ngml 1 during 6
days). After 28 days, matrix mineralization was revealed with alizarin red staining. Representative wells are shown (2 cm2). (d) MSC proliferation was
stimulated with 10% serum or PDGF-BB (5 ngml 1), in the presence of IL-1b at increasing concentration. After 72 h, cell number increase was measured.
(e) Migration of MSCs through a transwell was induced by 10% serum or by PDGF-BB (5 ngml 1), in the presence of IL-1b (1 ngml 1). After 6 h,
the number of cells per square millimetre that passed through the transwell was counted. (f) MSCs in OIM were treated once with IL-1b (1 ngml 1 during 4
days). After 7 and 14 days, expression of osteoblast-speciﬁc genes was determined by quantitative PCR. Fold changes in gene expression relative to MSCs
cultured in normal medium are shown. Alpl, alkaline phosphatase; Runx2, runt-related transcription factor 2; Ibsp, integrin-binding sialoprotein. For d–f, data
are means±s.e.m. (nZ3). **Po0.01, ***Po0.001; Student’s t-test. (g) MSCs in OIM were treated once with IL-1b (1 ngml 1) during 4 days. After 28
days, matrix mineralization was revealed with alizarin red staining. Representative wells (2 cm2) are shown.
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Fig. 12). The inhibitory effects of IL-1b and their magnitudes
were very similar to the ones observed with bone-derived MSCs.
Therefore, we chose to use bone-derived MSCs for all the
subsequent experiments involving MSCs. Lastly, we tested the
effects of IL-1R1/MyD88 signalling on osteoblasts. IL-1b
inhibited osteoblast proliferation, migration and differentiation
(Fig. 4). However, the effects of the cytokine were less strong on
osteoblasts compared with MSCs, suggesting that the inhibitory
effects of IL-1R1/MyD88 signalling are more severe on progenitor
cells.
Then, we examined whether proliferation and osteoblastic
differentiation of MSCs are also inhibited by IL-1R1/MyD88
signalling in vivo. As a model, carboxyﬂuorescein succinimidyl
ester (CSFE)-labelled MSCs from Il1r1 / , Myd88 / , or wt
mice were delivered into calvarial defects with a ﬁbrin matrix and
the labelled cells were recovered 7 days later using ﬂuorescence-
activated cell sorting. Myd88 / and Il1r1 / MSCs showed
signiﬁcantly less ﬂorescence (Fig. 5a,b; Supplementary Fig. 13),
indicating that they proliferated more than wt MSCs. In addition,
expression of osteoblast differentiation markers (alkaline phos-
phates, runt-related transcription factor 2 and integrin-binding
sialoprotein) was signiﬁcantly higher inMyd88 / and Il1r1 /
MSCs compared with wt MSCs (Fig. 5c), demonstrating that
differentiation of transplanted MSCs towards osteoblasts is
impaired by IL-1R1/MyD88 signalling. In addition, we examined
if mobilization of stem/progenitor cells following tissue injury is
also affected by IL-1R1/MyD88 signalling. As a model, calvarial
defects in Il1r1 / , Myd88 / or wt mice were treated with a
ﬁbrin matrix containing PDGF-BB—a very potent recruiting
factor for stem/progenitor cells35. After 7 days, the cells recruited
in the remodelled ﬁbrin matrix were analysed by ﬂow cytometry.
The percentage of MSC-like cells expressing typical surface
markers of MSCs (CD45 , CD90þ , CD44þ , Sca-1þ and
CD29þ ) was twice higher in Il1r1 / and Myd88 / mice
compared with wt mice (Fig. 5d; Supplementary Fig. 14).
IL-1b impairs the Akt/GSK-3b/b-catenin pathway in MSCs. To
gain insights on the molecular mechanism by which IL-1R1/
MyD88 signalling inhibits MSC proliferation and migration, we
used an antibody array to analyse the phosphorylation state of
key intercellular signalling molecules following co-stimulation
with IL-1b and PDGF-BB (Supplementary Fig. 15). Among the
proteins tested, the strongest phosphorylation signal induced by
PDGF-BB was for the serine/threonine kinase Akt. In contrast,
Akt phosphorylation at Thr308 and Ser473 considerably decreased
over time, when cells were co-stimulated with IL-1b (Fig. 6a),
indicating that IL-1R1/MyD88 signalling inhibits the Akt
pathway. Then, since Wnt/b-catenin signalling is critical for the
differentiation of MSCs into osteoblasts36,37, we investigated if
IL-1R1/MyD88 signalling disturbs this pathway, by analysing the
phosphorylation state of b-catenin following stimulation with
IL-1b. IL-1b induced b-catenin phosphorylation, indicating that
b-catenin was undergoing degradation. Conﬁrming b-catenin
degradation, the total concentration of b-catenin decreased
gradually over time (Fig. 6b). In addition, we examined whether
b-catenin degradation induced by IL-1R1/MyD88 signalling is
linked to a decrease of Akt activity. We focused on GSK-3b,
which is a kinase within the b-catenin destruction complex,
because Akt inactivates GSK-3b by phosphorylation of Ser9
(ref. 38). In MSCs that were stimulated with IL-1b, the
concentration of phosphorylated GSK-3b gradually decreased
over time (Fig. 6c), indicating that IL-1R1/MyD88 signalling
inhibits the Akt/GSK-3b/b-catenin singling pathway.
To verify that Akt activity and b-catenin directly contribute to
MSC proliferation, migration, differentiation and MSC-driven
bone regeneration, we used speciﬁc inhibitors for Akt and
b-catenin, respectively, MK-2206 and XAV-939. MK-2206
directly inhibits Akt phosphorylation at Ser473 and Thr308, while
XAV-939 promotes b-catenin degradation through stabilization
of axin39. Firstly, both inhibitors were conﬁrmed to be effective








































































































Figure 4 | IL-1b slightly inhibits proliferation migration and differentiation of osteoblasts. (a) Osteoblast proliferation was stimulated with 10% serum
or PDGF-BB (10 ngml 1), in the presence of 5 ngml 1 of IL-1b. After 72 h, the cell number increase was measured. Data are means±s.e.m. (n¼ 3).
(b). Osteoblast migration through a transwell was induced by 10% serum or PDGF-BB (5 ngml 1), in the presence of IL-1b (1 ngml 1). After 6 h, the
number of cells per square millimetre that passed through the transwell was measured. Data are means±s.e.m. (n¼ 3). (c) Osteoblasts in osteogenesis
induction medium (OIM) were treated once with IL-1b (1 ngml 1 during 4 days). (d) After 28 days, matrix mineralization was revealed with alizarin red
staining. Representative wells are shown. For a–c, data are means±s.e.m. (nZ3). *Po0.05, **Po0.01; Student’s t-test.
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inhibition by MK-2206 signiﬁcantly inhibits proliferation,
differentiation and migration of MSCs (Fig. 6d–f). Moreover,
similarly to the effect IL-1b, MK-2206 induced the
dephosphorylation of GSK-3b (Fig. 6c). Promotion of b-catenin
degradation by XAV-939 had no signiﬁcant effect on MSC
proliferation (Fig. 6d) and migration (Fig. 6e), but signiﬁcantly
reduced MSC differentiation into osteoblasts (Fig. 6f). Lastly, we
veriﬁed that Akt and b-catenin pathways are important for bone
regeneration stimulated by MSC delivery. As a model, we treated
calvarial defects with Il1r1/Myd88 / MSCs co-delivered with
MK-2206 or XAV-939 and we analysed regeneration after 4
weeks. Since Il1r1/Myd88 / MSCs are not responsive to IL-1,
their Akt activity and b-catenin level were affected by the
inhibitors, but not by IL-1 present in the defect micro-
environment. The regeneration induced by Il1r1/Myd88 /
MSCs co-delivered with inhibitors was signiﬁcantly lower
compared with regeneration-induced Il1r1/Myd88 / MSCs
delivered alone (Fig. 6g,h), showing that both Akt and b-catenin
pathways are critical for MSC-driven bone regeneration.
Inhibition of IL-1R1/MyD88 signalling promotes regeneration.
Since we found that IL-1R1/MyD88 signalling represses the
regenerative capacities of MSCs, we thought to inhibit this
pathway to create a pro-regenerative niche supporting
endogenous and transplanted stem cells. As a proof of concept,
we engineered a cell delivery system based on ﬁbrin matrix
functionalization with IL-1R1/MyD88 signalling inhibitors.
We chose two different strategies: (i) delivering the natural
inhibitor of IL-1R1, IL-1Ra; (ii) delivering a MyD88 inhibitory
peptide, RDVLPGTCVNS (MyD88-I)40, which inhibits MyD88
homodimerization. To deliver MyD88-I accurately, MyD88-I was
engineered to be covalently crosslinked into ﬁbrin matrix and to
translocate into cells. A ﬁbrin-binding sequence derived from
a2-plasmin inhibitor41 (a2-PI1-8, NQEQVSPL) was added at the
N terminus of the peptide, followed by a plasmin/matrix
metalloproteinase-sensitive sequence42 (VPMSMRGG) and a
membrane translocation sequence derived from antennapedia/
homeobox protein43 (RQIKIWFQNRRMKWKK). Therefore, the
peptide is covalently crosslinked into ﬁbrin, during the natural
polymerization process of the matrix41. Then, following matrix
remodelling, the peptide is released by proteases, translocates into
cells and ultimately inhibits IL-1R1 signalling (Fig. 7a). First, we
conﬁrmed that the engineered peptide could inhibit IL-1R1/
MyD88 signalling, as shown by its ability to signiﬁcantly impair
the release of cytokines from MSCs following stimulation with
IL-1b (Supplementary Fig. 17). Next, we used the critical calvarial
defect model again for testing the cell delivery system, since this
versatile model allows for evaluation of biomaterials and bone
tissue engineering approaches within a reproducible orthotopic
site25,44. Bone defect were treated with or without MSCs co-
delivered with IL-1Ra (1 mg) or a2PI1-8-MyD88-I (4 mg). Analysis
of bone regeneration after 2 month revealed that delivering
IL-1Ra or a2PI1-8-MyD88-I alone improves bone regeneration
compared with treatment with ﬁbrin only (Fig. 7b,c). Strikingly,
treatment with MSCs co-delivered with IL-1Ra or a2PI1-8-
MyD88-I led to a marked increase of bone tissue deposition as
to treatment with MSCs only, with no signs of bone overgrowth
and yielding coverage at 78% and 93%, respectively (Fig. 7b,c).
Discussion
Tissue injury and the following healing process are almost
always accompanied with an immune response. Therefore,






























































































































































Figure 5 | Transplanted MSC functions and mobilization of MSC-like cells are inhibited by IL-1R1/MyD88 signalling. (a–c) Carboxyﬂuorescein
succinimidyl ester (CFSE)-labelled MSCs from wt, Il1r1 / or Myd88 / mice were delivered into wt mouse calvarial defects (5mm diameter) within a
ﬁbrin matrix. After 7 days, partially remodelled ﬁbrin matrices were removed from the defect and digested to recover cells. (a) Difference in proliferation
between wt, Il1r1 / and Myd88 / MSCs was determined by comparing their ﬂuorescence intensity using ﬂow cytometry. MSC proliferation is
inversely proportional to the ﬂuorescence intensity. Representative histogram plots are shown. Black curves represent cells cultured in vitro with 1% serum
(no proliferation control). (b) Median ﬂuorescence of MSCs 7 days after implantation. Data are means±s.e.m. (n¼ 3). **Po0.01; Student’s t-test.
(c) CFSE-labelled MSCs were sorted by ﬂuorescence-activated cell sorting and further cultured in osteogenesis induction medium. Expression of
osteoblast-speciﬁc genes was determined by quantitative PCR, after 3 and 10 days. Fold changes in gene expression relative to MSCs cultured in normal
medium are shown. Alpl, alkaline phosphatase; Runx2, runt-related transcription factor 2; Ibsp, integrin-binding sialoprotein. (d) Calvarial defects in wt,
Il1r1 / or Myd88 / mice were treated with ﬁbrin matrices containing PDGF-BB (1mg). After 7 days, ﬁbrin matrices were recovered and digested to
recover cells. Percentages of MSC-like cells (CD90þ , CD45 , Sca-1þ , CD44þ and CD29þ cells) recruited within the matrices were analyzed by ﬂow
cytometry. Data are means±s.e.m. (n¼ 6 per condition). *Po0.05, **Po0.01, ***Po0.001; Student’s t-test.
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understanding the immune regulations of tissue repair and
regeneration could be fundamental for designing effective
regenerative therapies1,2. Particularly, the regenerative capacities
of endogenous and transplanted stem cells could rely on
the inﬂammatory/immune microenvironment at the injury
site1,2,23,45,46. For example, it has been shown that recipient
T cells negatively regulate bone formation by autologous MSCs,
in the mouse45. Moreover, MSC-mediated bone regeneration in
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Figure 6 | IL-1R1/MyD88 signalling impairs MSC functions via inhibition of the Akt/GSK-3b/b-catenin pathway. (a) MSCs were stimulated with
PDGF-BB (5 ngml 1), IL-1b (1 ngml 1) or both. Phosphorylation of Akt at Thr308 and Ser473 was quantiﬁed using an antibody array. Akt was measured
by enzyme-linked immunosorbent assay. (b,c) MSCs were treated with IL-1b (1 ngml 1). Phosphorylated b-catenin (pb-catenin), total b-catenin,
phosphorylated GSK-3b (pGSK-3b) and total GSK-3b were quantiﬁed using enzyme-linked immunosorbent assay. (d) MSC proliferation was stimulated by
PDGF-BB (5 ngml 1) with PBS, Akt inhibitor (MK-2206, 10mM), or b-catenin inhibitor (XAV-939, 10mM). After 72 h, cell number increase was measured.
(e) Migration of MSCs through a migration transwell was induced by PDGF-BB (5 ngml 1) with PBS, MK-2206 (10 mM), or XAV-939 (10mM). After 6 h,
the number of cells per square millimetre that passed through the transwell was counted. (f) MSCs in osteogenesis induction medium were treated with
PBS, MK-2206 (10mM), or XAV-939 (10 mM). After 7 and 14 days, expression of osteoblast-speciﬁc genes was determined by quantitative PCR. Fold
changes in gene expression relative to MSCs cultured in normal medium are shown. Alpl, alkaline phosphatase; Runx2, runt-related transcription factor 2;
Ibsp, integrin-binding sialoprotein. For a–f data are means±s.e.m. (nZ3). **Po0.01, ***Po0.001; Student’s t-test. (g,h) Critical size calvarial defects
(5mm diameter) in mice were treated with Il1r1/Myd88 / MSCs co-delivered in ﬁbrin matrix with saline, MK-2206 (1mM), or XAV-939 (1mM). Four
weeks after treatment, bone regeneration was measured by microCTas coverage of the defect. Data are means±s.e.m. (n¼6 per condition). ANOVA with
Bonferroni post hoc test for pair-wise comparisons; ***Po0.001. Representative calvarial reconstructions are shown in h. Original defect area is shaded with
a red dotted outline. ANOVA, analysis of variance.
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the rat has been enhanced, by inhibiting of NF-kB, which is a
major transcription factor regulating both the innate and adaptive
immune response. As another example, we recently found
that self-RNA released after radiation-induced injury promote
crypt stem cells death through TLR3 signalling23. Since tissue
injury and the healing response usually lead to the release of
endogenous danger signals such as TLR and IL-1R1 ligands10,11,
and because TLRs and IL-1R1 have been shown to inﬂuence the
repair of several tissues13–23,47, our initial motivation was to
determine the impact of TLR/IL-1R1 signalling during bone
regeneration.
While some TLRs have been shown to have a role in the repair
of certain organs including brain16,19,20, heart13,47, liver14,
kidney15 and skin22, all TLR knockout mice that we tested
displayed normal bone regeneration in speciﬁc pathogen-free
conditions. In contrast, MyD88- and IL-1R1-deﬁcient mice
exhibited better bone regeneration, indicating that IL-1R1/
MyD88 signalling negatively regulates bone regeneration. Since
IL-1R1/MyD88 signalling is well known to modulate the activity
of immune cells, we ﬁrst suspected that this signalling was
inhibiting bone regeneration by acting on the immune cells
mobilized after injury. However, using the chimeric mouse model
where bone marrow-derived immune cells and osteoclasts are
deﬁcient for MyD88, we found that IL-1R1/MyD88 signalling
inhibits bone regeneration by acting on tissue-resident cells
except osteoclasts. An ideal way to determine if IL-1R1/MyD88
signalling negatively regulated the regenerative capacity of MSCs
in vivo would have been to analyse bone regeneration in a mouse
having only these cells deﬁcient for IL-1R1 or MyD88.
Unfortunately, due to the lack of very speciﬁc markers for
MSCs, there are currently no accurate methods to create such
conditional knockout mouse. Therefore, as a model to explore
whether IL-1R1/MyD88 signalling inhibits MSC-driven bone
regeneration, we compared bone healing stimulated by the local
delivery of bone-derived MSCs from wt, Il1r1 / or Myd88 / .
We found that a much better regeneration is induced by Il1r1 /
or Myd88 / MSCs, indicating that IL-1R1/MyD88 signalling
inhibits bone regeneration induced by MSCs.
Among IL-1R1 ligands26 (IL-1a, IL-1b and IL-1Ra), we
observed that IL-1b and IL-1Ra are present at relatively high
concentration in the defect during the ﬁrst 10 days following
calvarial injury, while the concentration of IL-1Ra drastically
increases afterward. This observation suggests that the
IL-1R1/MyD88 signalling inhibiting bone regeneration in this
model occurs for at least 1 week post injury. Interestingly, the
concentration of IL-1b was about twice lower in calvarial defects
of mice having a much lower number monocytes/macrophages,
showing that these immune cells signiﬁcantly contribute to the
presence of IL-1b. Nevertheless, other cell types such as recruited
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Figure 7 | Inhibition of IL-1R1/MyD88 signalling promotes MSC-driven bone regeneration. (a) Design of the MyD88 inhibitor peptide
(a2PI1-8-MyD88-I). A ﬁbrin-binding sequence derived from a2-PI1-8 (NQEQVSPL, in grey) is followed by a plasmin/matrix metalloproteinase-sensitive
sequence (VPMSMRGG, in blue), a membrane translocation sequence (RQIKIWFQNRRMKWKK, in orange) and the MyD88 inhibitor peptide
(RDVLPGTCVNS, in red). The peptide is covalently crosslinked into ﬁbrin ﬁbres (in grey) during the natural polymerization process of the matrix via the
transglutaminase activity of factor XIIIa. Then, following matrix remodeling, the peptide is released by proteases (represented as scissors), translocates into
cells, and ultimately inhibits IL-1R1/MyD88 signalling. (b,c) Critical size calvarial defects (5mm diameter) in mice were treated with or without MSCs
delivered by a ﬁbrin matrix. Fibrin matrices were functionalized with IL-1Ra (1 mg) or a2PI1-8-MyD88-I (4 mg). Eight weeks after treatment, bone regeneration
was measured by microCTas coverage of the defect and bone volume. Data are means±s.e.m. (n¼ 6 per condition). ANOVA with Bonferroni post hoc test
for pair-wise comparisons; **Po0.01, ***Po0.001. Representative calvarial reconstructions are shown in c.
Original defect area is shaded with a red dotted outline. ANOVA, analysis of variance.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11051
8 NATURE COMMUNICATIONS | 7:11051 | DOI: 10.1038/ncomms11051 | www.nature.com/naturecommunications
contribute to the presence of IL-1b in the defect
microenvironment. In addition, in the case of transplanted
MSCs, the stem cells could also release IL-1b. Importantly, we
found that IL-1b signiﬁcantly impairs colony formation of freshly
isolated (primary) MSCs, as well as their differentiation towards
osteoblasts. Although MSCs phenotype and proprieties can
change during in vitro expansion, a strong inhibitory effect of
IL-1b was also observed in cultured (expended) MSCs, indicating
that IL-1b affects both primary and in vitro-expanded MSCs.
Notably, while primary bone-derived MSCs and primary bone
marrow-derived MSCs were reported to differ in stem cells
antigen-1 and nestin expression, c.f.u.-F and osteoblastic
differentiation potential48,49, the inhibitory effects of IL-1R1/
MyD88 signalling on bone-derived MSC and bone marrow-
derived MSC were the same. IL-1b also inhibited proliferation,
migration and differentiation of osteoblasts, but the inhibitory
effects of IL-1b on osteoblasts were less strong, compared
with MSCs, suggesting that IL-1R1/MyD88 signalling most
likely inhibits bone regeneration by acting principally on
stem/progenitor cells. Tracing the fate of transplanted wt,
Myd88 / and Il1r1 / MSCs, we could demonstrate that
both proliferation and osteoblastic differentiation of MSCs
delivered in bone defect are impaired by IL-1R1/MyD88
signalling. Moreover, when we examined the mobilization of
stem/progenitor cells following bone injury, Myd88 / and
Il1r1 / mice—having no cells responsive to IL-1b—mobilized
a higher percentage of cells having typical MSC markers. The cell
population detected within the defects most likely contained
MSCs, while other cell types that also express MSC markers such
as pericytes50 could have been detected. Still, IL-1R1/MyD88
signalling probably inhibits the mobilization of MSCs in the
defect, since IL-1b strongly inhibits MSC migration in vitro, and
because Il1r1 / and Myd88 / mice recruit more MSC-like
cells after bone injury.
Exploring the signalling mechanism by which IL-1b inhibits
MSC regenerative functions, we ﬁrst found that IL-1b promotes
the dephosphorylation of Akt. Therefore, since Akt is a central
node in cell signalling downstream many growth factor receptors
such as PDGF and ﬁbroblast growth factor receptors38,
IL-1R1/MyD88 signalling probably attenuates MSC response to
most Akt-dependent growth factors. Secondly, we found that
IL-1b induces b-catenin phosphorylation and degradation,
suggesting that IL-1R1/MyD88 directly impairs canonical Wnt
signalling, which is critical for MSC differentiation into
osteoblasts36,37. Interestingly, these ﬁndings are in line with
another study demonstrating that NF-kB—which is activated by
IL-1R1 signalling26—promotes b-catenin degradation in MSCs
and impairs their differentiation into osteoblasts51. Moreover, we
found that b-catenin degradation induced by IL-1b is linked to an
increase of active GSK-3b (unphosphorylated) via a decrease of
active Akt (unphosphorylated). Taken together, our data show
that IL-1R1/MyD88 signalling inhibits the Akt/GSK-3b/b-catenin
singling pathway in MSCs. Yet, the detailed molecular
mechanism by which this signalling pathway is inhibited still
needs to be determined. For instance, IL-1b could stimulate the
expression of phosphatases speciﬁc for Akt or induce the
expression of proteins involved in b-catenin degradation.
Interestingly, it has been shown that NF-kB activation in MSCs
promotes b-catenin ubiquitination and degradation through
induction of E3 ubiquitin-protein ligase Smurf1 and Smurf2
(ref. 51), giving some insights about possible mechanisms. We
could also show that the Akt and b-catenin pathways directly
contribute to MSC proliferation, migration and differentiation,
using potent and selective inhibitors for these molecules.
As expected, Akt activity was critical for MSC migration,
proliferation and differentiation, since these processes are
known to be dependent on Akt38,52. On the other hand,
b-catenin is probably weakly involved in MSC proliferation and
migration, since b-catenin inhibition principally affected MSC
differentiation into osteoblasts. Nevertheless, Akt and b-catenin
pathways have been shown to positively regulate bone
healing52,53. By co-delivering the inhibitors in vivo, we were
also able to observe that both pathways are essential for bone
regeneration induced by MSC delivery.
After having revealed that IL-1R1/MyD88 signalling inhibits
the regenerative potentials of MSCs, we engineered a proof of
concept MSC delivery system based on ﬁbrin matrix functiona-
lization with IL-1R1/MyD88 signalling inhibitors. As a ﬁrst
inhibitor, we chose IL-1Ra, since the protein is the natural
antagonist of IL-1R1. Moreover, just as ﬁbrin, IL-Ra is clinically
relevant, since the molecule is clinically available for the
treatment of rheumatoid arthritis. As a second inhibitor, we
chose to deliver a2PI1-8-MyD88-I, because synthetic peptide
delivery could be more cost effective than recombinant protein
delivery. Strikingly, we found that delivering MSCs with IL-1Ra
or a2PI1-8-MyD88-I led to a large increase of bone tissue
deposition as to treatment with MSCs only. Interestingly,
a2-PI1-8-MyD88-I was slightly more efﬁcient than IL-1Ra,
yielding coverage near to 100%. This difference could be
explained by the higher concentration of the peptide used
compared with IL-1Ra (20 versus 2 mM) and because
a2-PI1-8-MyD88-I was engineered to be released in a controllable
manner following ﬁbrin matrix remodelling. Yet, the delivery of a
ﬁbrin-binding version of IL-1Ra or the co-delivery of IL-1Ra with
a2-PI1-8-MyD88-I at lower doses could be very effective. In
addition, while the calvarial critical size defect is a well-accepted
model that is usually considered as translationally relevant25,44,
further tests will be required to predict the clinical potential of
IL-1R1/MyD88 signalling inhibition. Experiments in more
realistic models would also conﬁrm the physiological relevance
of the ﬁndings. Typically, these tests would be done using critical
size bone defect models in larger animal closer to human such as
dogs, goats or sheep, since success in rodents is not enough to
open the door for human trials24,54.
Most importantly, we demonstrated that MSCs delivered
without an inhibitor of IL-1R1/MyD88 signalling could not
promote regeneration, reﬂecting that one cannot assume that
stem/progenitor cells automatically stimulate tissue healing. In
other words, applying stem cells to damaged tissue with little or
no attempt to prepare and engineer the regenerative niche is
unlikely to promote engraftment2. Indeed, several studies have
shown that MSCs from different sources are inefﬁcient in
promoting bone regeneration45,51,55,56. Moreover, regenerative
medicine therapies based on stem cells did not yet demonstrate
real effectiveness in the clinic4,57,58. Our poor understanding of
how transplanted cells are controlled by the host tissue is
probably one the main reasons underlying this modest translation
to the clinic. On the front line, understanding and controlling the
immune microenvironment at the delivery site could be the key
to improve the efﬁcacy of stem cell-based therapies2. Here, we
revealed that the innate immune response via IL-1R1/MyD88
signalling impairs bone regeneration and the regenerative
capacity of MSCs. By using a simple stem cell delivery
integrating an inhibitor of IL-1R1/MyD88 signalling, we could
considerably improve MSC-driven bone regeneration.
Furthermore, such a strategy may be adapted into cell delivery
systems using other biomaterial matrices or for MSC-based
regenerative strategies targeting other tissues. This work
highlights the crucial role of the innate immune response in
modulating the regenerative capacity of stem cells and the
importance of integrating a control of the host immune
microenvironment into regenerative strategies.
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Methods
Animals. All animals were kept under speciﬁc pathogen-free conditions. Wt
C57BL/6 mice were purchased from SLC Japan. Myd88 / (ref. 59), Trif /
(ref. 60), Tlr1 / (ref. 61), Tlr5 / (ref. 62), Tlr7 / (ref. 63), Tlr2/4/9 /
(refs 64–66) and Il1r1 / (ref. 59) mice were backcrossed onto a C57BL/6
background for more than eight generations. All animal experiments were
performed with the approval of the Animal Research Committee of the Research
Institute for Microbial Diseases (Osaka University).
Calvarial defect model. Mice used for surgery were 10–12 weeks old. Mice were
anaesthetized with isoﬂurane. The top of their head was shaved and a longitudinal
incision was performed to reveal the skull. Bone tissue was exposed by retracting
the soft tissues. Using a drill, two craniotomy defects (5mm diameter) were created
in the parietal bones of the skull on each side of the sagittal suture line. The defects
were washed with saline and covered with a ﬁbrin matrix polymerized atop the
dura (40 ml per defect, 10mgml 1 ﬁbrinogen (Enzyme Research Laboratories),
2Uml 1 of thrombin (Sigma-Aldrich), 5mM CaCl2, 25mgml 1 aprotinin
(Roche), 2 106 MSCs). For Akt and b-catenin inhibition experiments, MK-2206
or XAV-939 were added to the MSC mix to have a ﬁnal concentration of 1mM per
ﬁbrin matrix. Then, the soft tissue was closed with stitches. As a painkiller, mice
received a subcutaneous injection of Tramdol (100mg kg 1).
Microcomputed tomography. Skulls were scanned with a Scan-Xmate
RB080SS110 system (Comscan Techno Co., Ltd) for screening and with a microCT
40 (Scanco Medical AG) operated at energy of 70 kVp and intensity of 145ms for
detailed measurements. Scans were performed at high-resolution mode resulting in
a nominal isotropic resolution of 30 mm. After reconstruction, a 3D Gaussian ﬁlter
(sigma 1.2, support 1) was applied to all images. Bone was segmented from
background using a global threshold of 22.4% of maximum grey value. Afterwards,
cylindrical masks were placed manually at the defects. Bone volume within these
masks was calculated using a standardized procedure developed for quantitative
bone morphometry67. Coverage was calculated on a dorso-ventral projection of the
cylindrical area68.
Chimeric mice. Bone marrow cells (1 107) from 5-week-oldMyD88 / mice or
wt mice were intravenously injected into lethally irradiated 4-weeks-old recipient
wt mice. Mice were placed on 10ml l 1 neomycin sulfate for 2 weeks post
radiation. After 6 weeks, most of bone marrow-derived immune cells and
osteoclasts in bone tissue should lack MyD88 (ref. 69). Mice were used for cranial
surgery 8 weeks after bone marrow transplantation as described for the calvarial
defect model. After 4 weeks, skulls were analysed by microCT and bone marrow
from femurs was harvested to conﬁrm the absence of MyD88 in chimeric mice.
Bone marrow-derived cells were lysed with tissue protein extraction reagent
(T-PER, Thermo Scientiﬁc) supplemented with protease inhibitor cocktail
(one tablet of protease inhibitor cocktail (Roche) for 10ml). The lysed cells were
centrifuge at 5,000g for 5min and the supernatant was analysed using ELISA
for MyD88 (MyBioSource).
Release of cytokines and inﬂammatory-associated molecules following bone
injury. Calvarial defect (4mm diameter) were treated with a ﬁbrin matrix as
described for the calvarial defect model. After 1, 3, 6, 10 and 15 days, the partially
remodelled matrix and the bone tissue surrounding the defect (1mm farther) was
collected. As a control a 5mm diameter calvarial bone tissue was collected (day 0).
Fibrinous matrices and tissue samples were incubated in 1ml of tissue protein
extraction reagent (T-PER, Thermo Scientiﬁc) containing protease inhibitors
(one tablet of protease inhibitor cocktail (Roche) for 10ml) and homogenized with
a tissue homogenizer. Tissue lysates were incubated 1 h at 37 C and centrifuged at
5,000g for 5min. Supernatants were stored at  80 C. Cytokines were detected
using an antibody array (Mouse Cytokine Array Panel A, R&D Systems) and by
ELISA (Mouse IL-1 beta/IL-1F2 DuoSet and Mouse IL-1ra/IL-1F3 DuoSet,
R&D Systems) according to the manufacturer’s instructions. For the antibody
array, 400ml of lysate was used. The chemiluminescent signals were detected
using ImageQuant LAS 4000 and quantiﬁed with ImageQuant TL software
(GE Healthcare Life Sciences). A measured volume over 1 106 was considered
as a positive signal.
Monocytes/macrophages depletion. One day before surgery, 200ml of
clodronate liposomes or empty liposomes (Anionic liposomes, FormuMAx
Scientiﬁc Inc.) was intravenously injected in wt mice. Additional 50 ml of
clodronate liposomes or empty liposomes was intravenously injected right before
surgery and every 2 days until day 6. The concentration of IL-1b into the defect was
measured by enzyme-linked immunosorbent assay (ELISA) as described above.
The efﬁciency of monocytes/macrophages depletion was checked by measuring the
percentage of CD11bþ cells in the spleen by ﬂow cytometry (anti-mouse CD11b,
Biolegends).
Isolation of bone-derived MSCs. Long bones of arms and legs of wt, Myd88 /
and Il1r1 / mice (6–8 weeks old) were detached from the body trunk. All
muscles and cartilages were removed. The bones were rinsed with PBS and cut into
three pieces, to have one diaphysis part and two metaphyses/epiphyses parts. The
bone marrow within the medullary cavity of the diaphyses was ﬂushed out using a
27-Gauge needle attached to a 10ml syringe ﬁlled with a-MEM containing 1% fetal
bovine serum (FBS). Bones pieces, including diaphyses and metaphyses/epiphyses
were washed with PBS and cut into 1–3mm3 pieces. Bone chips were transferred in
a 25 cm2 cell culture-treated ﬂask with 3ml of a-MEM medium containing 2mM
L-glutamine, 100mgml 1 penicillin/streptomycin, 10% FBS, and 1mgml 1
collagenase type II (Life Technologies). Bone chips were digested for 1 h at 37 C to
release most of hematopoietic cells on the inner interface of the bones. Then, the
bone chips were washed with MSC culture medium (a-MEM, 2mM L-glutamine,
100mgml 1 penicillin/streptomycin, 10% heat inactivated MSC-certiﬁed FBS
(Gibco)) and incubated at 37 C with 5% CO2 in 6ml of MSC culture medium.
Bone chips were kept in culture for 6 days with one medium change at day 3. Then,
the MSCs that have migrated out of the bone chips and formed colonies were
detached using trypsin/EDTA. Cells were splitted at a ratio of 1:3 (passage 0) and
the bone chips were reseeded together for allowing MSCs to continue migrating out
for 3 more days. Five independent isolates were pulled together and MSCs were
further expended for three passages before storage. The expression of MSC-speciﬁc
surface marker was veriﬁed using ﬂow cytometry. MSCs were stained for 15min in
100 ml of ﬂow cytometry buffer (PBS containing 2% of heat inactivated serum)
containing anti-mouse antibodies (Biolegends): CD11, CD14, CD19, CD34,
CD45.2, Ly-6 A/E (Sca-1), CD29, CD44, CD75 and CD90.1. Cells were washed
twice with ﬂow cytometry buffer and further analysed by ﬂow cytometry (BD
FACSCanto II). For cells used in colonies formation assay, bone pieces were gently
disrupted using a mortar and pestle, in washing buffer (PBS with 2% FBS and
1mM EDTA). Disrupted bone was rinsed with PBS containing 2% FBS and 1mM
EDTA until bone fragments turned white. Then, bone fragments were transferred
to a 100mm dish containing a collagenase solution (2ml of 0.25% collagenase
Type I (Stemcell Technologies) in PBS containing 20% FBS). Using a scalpel,
bone fragments were cut into small pieces (1–2mm) and transferred into a 50ml
polypropylene tube with 10ml collagenase solution. Bone fragments were digested
at 37 C under agitation for 45min. Then, 30ml of washing buffered was added
and supernatant was ﬁltered through a 70 mm cell strainer. Cells were centrifuged at
300g for 10min and resuspend in 500 ml of medium. Lastly, CD45þ cells were
depleted (MagCellect Mouse Mesenchymal Stem Cell Isolation Kit, R&D Systems)
before colonies formation assays.
MSC isolation from bone marrow. Long bones of arms and legs of wt (6–8 weeks
old) were detached from the body trunk. All muscles and cartilages were removed
and the bones were rinsed with PBS. The bone marrow was ﬂushed out using a
27-Gauge needle attached to a 10ml syringe ﬁlled with a-MEM containing 1% FBS.
Bone marrow cells were passed through a 70 mm ﬁlter mesh and transferred in
tissue culture-treated plate at a density of 2.5 107 cells per ml 1. Cells were
incubated at 37 C with 5% CO2 in a humidiﬁed chamber for 4 h. Non-adherent
cells were removed by changing the medium to culture medium (a-MEM con-
taining 2mM of L-glutamine, 100mgml 1 penicillin/streptomycin, and 10% FBS).
Thereafter, medium was replaced every 8 h. After 72 h, cells were washed with PBS
and new medium was added. Then, medium changed every 3–4 days. After 2–3
weeks, MSC colonies formed were detached using trypsin/EDTA (passage 0). MSCs
were expanded until 3 passages. For cells used in colonies formation assay, CD45þ
cells were depleted (MagCellect Mouse Mesenchymal Stem Cell Isolation Kit, R&D
Systems).
Colony formation assay. Primary cells were seeded in six-well plates
(50 bone-derived cells) or 12-well plates (200 bone marrow-derived cells) and
cultured in medium (a-MEM, 100mgml 1 penicillin/streptomycin, 20% FBS)
with or without 1 ngml 1 of IL-1b for 12 days. Medium was changed once after
6 days. Then, cells were washed with PBS and stained with an ice-cold crystal violet
solution (0.5% in methanol). The number of colony (450 cells) was counted and
their size was measured using ImageJ software. For osteobalstic differentiation of
colonies, primary cells (50 bone-derived cells) were seeded in 24-well plate with
osteogenesis induction medium (a-MEM with 2mM of L-glutamine, 10% FBS,
100mgml 1 penicillin/streptomycin, 50 mM ascorbate-phosphate, 10mM
b-glycerolphophate and 100 ngml 1 of human BMP-2 (R&D Systems)) with or
without 1 ngml 1 of IL-1b. After 28 days, cells were ﬁxed with ice-cold methanol
and calciﬁed nodules were stained using a calciﬁed nodule staining kit (AK-21;
Primary Cell).
Osteoblast isolation. Calvariae from 3-day-old mice were isolated and
further digested in a-MEM containing enzymes (0.1% collagenase type II (Life
Technologies), 0.2% dispase (Sigma-Aldrich)) at 37 C for 20min in a shaking
water bath to release calvarial cells. The supernatant containing released cells was
transferred in a new tube, centrifuged at 300 g, and the pellet was resuspended in
medium (a-MEM, 100mgml 1 penicillin/streptomycin, 10% FBS). The calvariae
were digested three more times for a total of four digestions. Digestions 3 and
4 containing osteoblasts were pulled together and transferred in a tissue
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11051
10 NATURE COMMUNICATIONS | 7:11051 | DOI: 10.1038/ncomms11051 | www.nature.com/naturecommunications
culture-treated plate at a density of 3 105 cells ml 1. Calvarial cells were then
maintained in culture for 2 weeks in osteogenesis inducing medium (a-MEM with
2mM of L-glutamine, 10% FBS, 100mgml 1 penicillin/streptomycin, 50 mM
ascorbate-phosphate, 10mM b-glycerolphophate, 100 ngml 1 of human BMP-2
(R&D Systems)) and stored before use.
Cell proliferation assays. Proliferation assays were performed as described
previously70. Brieﬂy, cells were starved 24 h with a-MEM containing 1% FBS.
Then, cells were seeded in 96-well plate with a-MEM containing murine PDGF-BB
(5 ngml 1, Peprotech) and 1% FBS, or a-MEM containing 10% FBS. Directly
after, murine IL-1b (Peprotech) was added at concentrations ranging from 1 to
1,000 ngml 1. For Akt and b-catenin inhibition experiments, MK-2206 (AdooQ
Bioscience) or XAV-939 (AdooQ Bioscience) were added instead of IL-1b at a
concentration of 10 mM. After 72 h, cell number was quantiﬁed using PrestoBlue
dye (Invitrogen). Percentage proliferation increases were calculated over basal
proliferation (medium with 1% FBS and no PDGF-BB).
Migration assays. Migration assays were performed as described previously70.
Brieﬂy, solutions containing murine PDGF-BB (5 ngml 1) with or without
1 ngml 1 of murine IL-1b were added to the bottom side of a collagen type I
(C4243, Sigma-Aldrich) coated transwell (8 mm pore size, Millipore). For Akt and
b-catenin inhibition experiments, MK-2206 or XAV-939 were added instead of
IL-1b at a concentration of 10 mM. Directly thereafter, cells (30,000 cells per
transwell) were added to the transwell upper chambers. After 6 h, the numbers of
cells that migrated to the bottom side of the membrane were counted. Membranes
of each insert were removed and mounted on microscopy glass slides using
Vectashield (Vector Laboratories) mounting medium containing DAPI. The
number of cells that migrated to the bottom side of the membrane was counted.
Osteoblastic differentiation assays. Cells were seeded on 24-well plate at
70–80% conﬂuency in osteogenesis inducing medium with or without murine
IL-1b (1 ngml 1). For Akt and b-catenin inhibition experiments, MK-2206 or
XAV-939 were added instead of IL-1b at a concentration of 10mM. After 4 days,
osteogenesis inducing medium was replaced (without IL-1b). Medium was changed
every 3–4 days. Seven or 14 days following stimulation with IL-1b, total RNAs were
isolated, using RNeasy Plus Mini Kit (Qiagen) and reverse transcription was
performed using ReverTra Ace (Toyobo Co., Ltd.). Quantitative PCR was
performed with an ABI PRISM 7500 using TaqMan Assay with the following
primers: Alpl Mouse, Mm00475834_m1; Runx2 Mouse, Mm00501580_m1;
Ibsp Mouse, Mm00492555_m1; Eukaryotic 18S rRNA Endogenous Control
(VIC/MGB Probe, primer limited) (Applied Biosystems). For extracellular matrix
mineralization analysis, MSCs were cultured for 28 days in osteogenesis inducing
medium. Then, cells were ﬁxed with methanol and calciﬁed nodules were stained
using a calciﬁed nodule staining kit.
Chondrogenic differentiation of MSCs. MSCs were transferred in a 15ml conical
tubes (250,000 cells per tube), centrifuged at 200g for 5min and resuspended in
D-MEM/F12. MSCs were centrifuged again and resupended in 0.5ml of
D-MEM/F12 containing 100mgml 1 penicillin/streptomycin, 1% ITS
supplement, 1 chondrogenic supplement (R&D Systems), with or without
murine IL-1b (1 ngml 1). Cells were centrifuged on more time at 200g for 5min
to form a pellet. The cap of the tubes were loosen to allow gas exchange and the
tubes were incubated upright at 37 C with 5% CO2. The medium was replaced
every 3 days (without IL-1b). After 28 days, the spheroids were washed with PBS
and ﬁxed with 10% formalin for 60min. Spheroids were washed twice with water
and stained with Alican Blue 8 GX (Sigma-Aldrich, 0.1mgml 1 in ethanol/acetic
acid solution (3:2)) overnight at room temperature in the dark. Spheroids were
destained three times with an ethanol/acetic acid solution (3:2) and resuspended in
PBS, before imaging.
Trophic factors secreted by MSCs. MSCs were seeded in six-well plates and
cultured until 70–80% conﬂuency. Cells were starved for 24 h with medium
containing 1% FBS and further stimulated with PBS or IL-1b (1 ngml 1).
After 24 h supernatants were collected and stored at  80 C. Trophic factors
were detected using an antibody array focusing on angiogenic factors (Mouse
Angiogenesis Antibody Array, R&D Systems) according to the manufacturer’s
instructions, using 400 ml of supernatant. The chemiluminescent signals were
detected using ImageQuant LAS 4000 and quantiﬁed with ImageQuant TL
software (GE Healthcare Life Sciences). A measured volume over 1 103 was
considered as a positive signal.
Intracellular signalling array. MSCs were seeded in six-well plate and cultured
until 60–70% conﬂuency. Cells were starved 24 h with a-MEM containing only 1%
FBS. Then, cells were stimulated with murine PDGF-BB (5 ngml 1), murine IL-1b
(1 ngml 1), or with both for 10min to 24 h. Phosphorylation and cleavage of
intrecellular signalling molecules were detected using an antibody array (PathScan
Intracellular Signalling Array, Cell Signalling) according to the manufacturer’s
instructions. The chemiluminescent signals were detected using ImageQuant LAS
4000 and quantiﬁed with ImageQuant TL software (GE Healthcare Life Sciences).
Akt signalling assay. MSCs were seeded in six-well plate and cultured until
60–70% conﬂuency. Then, cells were stimulated with murine IL-1b (1 ngml 1)
or PBS for 0 to 72 h. For Akt and b-catenin inhibition experiments, MK-2206 or
XAV-939 were added instead of IL-1b at concentrations ranging from 0 to 10 mM.
Total Akt and phosphorylated Akt were quantiﬁed using ELISA (InstantOne
ELISA, afﬁmetrix eBioscience) according to the manufacturer’s instructions.
Wnt/b-catenin and GSK-3b signalling assays. MSCs were seeded in six-well
plate and cultured until 60–70% conﬂuency. Then, cells were stimulated with
murine IL-1b (1 ngml 1) or PBS for 4 to 72 h. For Akt and b-catenin inhibition
experiments, MK-2206 or XAV-939 were added instead of IL-1b at a concentration
ranging from 0 to 10mM. Total b-catenin and phosphorylated b-catenin were
quantiﬁed using ELISA (InstantOne ELISA, afﬁmetrix eBioscience) according to
the manufacturer’s instructions. Total GSK-3b and phosphorylated GSK-3b were
quantiﬁed using ELISA (InstantOne ELISA, afﬁmetrix eBioscience) according to
the manufacturer’s instructions.
Proliferation of transplanted MSCs. Wt, Myd88 / and Il1r1 / MSCs were
cultured until 80–90% conﬂuency. Cells were washed with PBS and incubated with
10 mM of CSFE (Life Technologies) in PBS for 15min at 37 C. Thereafter, CSFE
solution was removed and replaced with a-MEM containing 10% FBS and further
incubated for 30min at 37 C. Cells were detached using trypsin/EDTA and
transplanted in cranial defect as described for the calvarial defect model
(2 106 cells per defect within a 40 ml ﬁbrin matrix). As non-proliferating cells
control, MSCs were seeded in cell culture plate with a-MEM containing only 1%
FBS. As a wt proliferating cells control MSCs were seeded in cell culture plate with
a-MEM containing 10% FBS or 10% FBS with 5 ngml 1 of PDGF-BB. Medium
was renewed after 4 days. Seven days after transplantation, the partially remodelled
ﬁbrinous matrices containing MSCs were removed from the defect and incubated
in 1ml of an enzyme solution (trypsin (10mgml 1) and collagenase II
(1mgml 1)) for 1 h at 37 C. Then, the digested matrix was resuspended in 10ml
of medium containing 10% serum, passed through a cell strainer and centrifuged.
The cells were resuspended in 1ml of red blood cell lysis buffer (Sigma-Aldrich),
incubated at room temperature for 5min, and resuspended in 10ml of ﬂow
cytometry buffer. For non-proliferating cells and wt proliferating cells controls,
cells were detached from cell culture plate using trypsin/EDTA and resuspended in
ﬂow cytometry buffer. Cells were washed twice with ﬂow cytometry buffer and
further analysed by ﬂow cytometry (BD FACSCanto II).
Osteoblastic differentiation of transplanted MSCs. As a non-differentiated
control, wt, Myd88 / and Il1r1 / MSCs were seeded in cell culture plate with
a-MEM containing 10% FBS for 7 days. At the same time, wt, Myd88 / and
Il1r1 / MSCs were labelled with CSFE, transplanted into calvarial defect,
and recovered from the defect, as described for the proliferation of transplanted
MSCs assay. Cells recovered from the ﬁbrin matrix were sorted using FACS
(BD FACSAria II), to isolate CSFE-labelled MSCs. After recovery, MSCs were
seeded on 24-well plate at 70–80% conﬂuency in osteogenesis inducing medium.
After 3 and 10 days, total RNAs were isolated and quantitative PCR was performed
as described for the osteoblastic differentiation assay.
Mobilization of MSC-like cells. Calvarial defects were treated with ﬁbrin matrix
(40 ml) containing 1 mg of murine PDGF-BB, as described for the calvarial defect
model. After 7 days, the partially remodelled ﬁbrinous matrices containing
endogenous cells were removed from the defect site and incubated in 1ml of an
enzyme solution as described for the proliferation of transplanted MSCs assay.
Isolated cells were stained for 15min in 100 ml of ﬂow cytometry buffer containing
antibodies (Biolegends, 1:200 dilution): anti-mouse CD29, anti-mouse Ly-6 A/E
(Sca-1), anti-mouse CD90.1, anti-mouse CD45.2, and anti-mouse CD44. Cells were
washed twice with ﬂow cytometry buffer and further analysed by ﬂow cytometry
(BD FACSCanto II).
Peptide inhibitor of IL-1R1/MyD88 signalling (a2PI1-8-MyD88-I). The peptide
a2PI1-8-MyD88-I (NQEQVSPLVPMSMRGGRQIKIWFQNRRMKWKKRDVLPG
TCVNS) was synthesized by GeneScript and veriﬁed as Z95.0% by HPLC. The
peptide was further dialyzed against HEPES buffer (20mM HEPES, 150mM NaCl,
pH 7.5). The capacity of the peptide to inhibit IL-1R1/MyD88 signalling was
assessed by monitoring the release of cytokines from MSCs following stimulation
with murine IL-1b. MSCs seeded in 24-well at 70–80% conﬂuency were stimulated
with 10 ngml 1 of IL-1b together with a2PI1-8-MyD88-I at increasing con-
centration (1–100 mgml 1). After 24 h, the concentration of IL-6, CCL2, CXCL1
and CXCL2 released were measured using ELISA (Mouse IL-6, CCL2/JE/MCP-1,
CXCL1/KC and CXCL2/MIP-2; DuoSets, R&D Systems).
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MSC delivery system containing inhibitors of IL-1R1/MyD88 signalling. Fibrin
matrices with or without wt MSCs were delivered into cranial defects as described
for the calvarial defect model (2 106 cells per defect). Fibrin matrices (40 ml per
defect, 10mgml 1 ﬁbrinogen, 2Uml 1 of thrombin, 5mM CaCl2, 25 mgml 1
aprotinin) were functionalized with 4 mg of a2PI1-8-MyD88-I or 1 mg of murine IL-
1Ra (R&D Systems). After 8 weeks, bone regeneration was analysed by microCT as
described above.
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